ArticleInflammatory bowel diseases2026
Persistence and safety of subcutaneous infliximab up to 1 year after switching from intravenous infliximab in pediatric inflammatory bowel disease: a multicenter real-world cohort study.
Article in Inflammatory bowel diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Subcutaneous infliximab for maintenance therapy in children and adolescents with inflammatory bowel disease: a systematic review and meta-analysis.European journal of pediatrics · 2026Pooled it
- Multiple switches between infliximab originator and biosimilars in pediatric inflammatory bowel disease.Journal of pediatric gastroenterology and nutrition · 2026Observational
- Subcutaneous infliximab as a maintenance option in pediatric IBD: a real-world cohort including younger and lower-weight children.Molecular and cellular pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionReal-world data regarding subcutaneous infliximab (SC-IFX) in patients with pediatric inflammatory bowel disease IBD (PIBD) is scarce. We evaluated SC-IFX as maintenance therapy in PIBD patients who switched to SC-IFX from intravenous infliximab (IV-IFX) treatment.
methodsIn this retrospective multicenter study we identified PIBD patients who switched to SC-IFX. The primary outcome was treatment persistence at up to 12 months post-switch. Secondary outcomes included relapse rate (defined as Pediatric Ulcerative Colitis Activity Index [PUCAI] ≥10/ weighted PCDAI ≥ 12.5 with biochemical/endoscopic evidence of disease activity), IFX trough levels, immunogenicity, safety, and acceptance.
resultsSixty-six patients switched to SC-IFX (48% males; median switch-age, 16.5 years; IQR, 14.9-17.3 years; median switch-weight, 60 kg; range, 13-102 kg), 41/66 (62%) with Crohn Disease. Pre-switch, the median IV-IFX maintenance dose was 10 mg/kg every 6 weeks; 58/66 patients (88%) were in clinical remission. The initial SC-IFX regimen was 120 mg every other week in 62/66 patients (94%). SC-IFX persistence was 78% (95% CI, 66-91) at 12 months post-switch, with 89% of patients persisting on IFX, either intravenous (IV) or subcutaneous (SC), at the end of follow-up. Relapses were observed in 11/66 patients (17%) over a median follow-up of 11.0 months (IQR, 5.1-12.0); 6 patients underwent SC-IFX dose intensification, with 3 successfully regaining clinical response. Regarding anti-drug antibodies (ADA), 3 out of 4 patients who were ADA positive on IV-IFX resolved post-switch. Overall, 19/66 patients (29%) reported 21 adverse events (AEs), including 3/21 severe AEs. The majority (53/66 patients; 80%) expressed a positive attitude toward SC-IFX.
conclusionsThe largest documented PIBD cohort switching to SC-IFX to date showed high treatment persistence at 1 year, confirming SC-IFX as an effective and safe maintenance alternative to IV-IFX.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.